Quest Diagnostics, US74834L1008

Quest Diagnostics outlines earnings timetable, shares tracked against US diagnostics peers

Veröffentlicht: 26.06.2026 um 14:25 Uhr, Redaktion AD HOC NEWS, Redaktionelle Verantwortung: Rafael Müller (Chefredaktion)

Quest Diagnostics has updated investors on its upcoming reporting dates while the NYSE-listed diagnostics group trades near the upper end of its 52-week range alongside peers such as Labcorp and Abbott.

Quest Diagnostics, US74834L1008
Quest Diagnostics, US74834L1008

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 14:25.

Quest Diagnostics (US74834L1008) sets the tone for NYSE investors with a clear timetable for its next financial updates. The diagnostics provider competes in the US with listed peers such as Labcorp and Abbott Laboratories, both part of the S&P 500 index.

What the calendar shows

Quest Diagnostics lists its quarterly earnings calls and investor conferences in the events section of its investor relations website, giving dates for upcoming presentations and webcasts for 2026. The group typically reports second-quarter figures in late July or early August, followed by a third-quarter update in late October.

For the most recent reported quarter, Quest Diagnostics posted revenue of around 2.4 billion USD and discussed trends in routine testing and esoteric diagnostics on its earnings call, according to company materials and analyst summaries.

How analysts value the stock

On the NYSE, Quest Diagnostics trades under the ticker DGX and closed the session of 2026-06-25 at roughly 206 USD, with a 52-week range from about 162 USD to just over 212 USD, according to recent market data.

Analyst data compiled by PandaForecast and other aggregators point to an average price expectation in the low-220 USD range for Quest Diagnostics, implying modest upside versus the latest close, while recent rating actions include at least one downgrade to Hold in May 2026 by Wall Street Zen.

Go deeper

Background and price data on Quest Diagnostics

News, key figures and historical data provide additional context for investors following Quest Diagnostics shares on the NYSE.

The business behind the ticker

Quest Diagnostics generates most of its revenue from diagnostic information services such as routine blood tests, advanced cardiovascular diagnostics and oncology-related testing. The company also offers anatomic pathology services and genomic sequencing in specialized laboratories across the United States.

Where the stock trades today

The Quest Diagnostics shares (US74834L1008) most recently traded on the NYSE at around 206 USD on 2026-06-25, according to recent closing data.

Key data on the Quest Diagnostics shares

  • Company: Quest Diagnostics Incorporated
  • ISIN: US74834L1008
  • WKN: 918895
  • Ticker: DGX
  • Trading venue: NYSE
  • Price (as of 2026-06-25, 21:59): 206.33 USD
  • Market cap: 23.0 billion USD (as of 2026-06-25)
  • Sector / industry: Health Care / Diagnostics & Research
  • Index membership: S&P 500
  • Next earnings date: not officially scheduled

More on the Quest Diagnostics shares in social media

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.

Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.

en | US74834L1008 | QUEST DIAGNOSTICS | boerse | 69633142 | bgmi